tapebrief
VEEV · Q3 2026

VEEV · Q4 2026 Earnings

Cautious

Veeva Systems

Reported March 4, 2026

30-second summary

Veeva closed FY2026 with Q4 revenue of $836M (+16% YoY) and non-GAAP EPS of $2.06, beating its own Q4 guide by ~$26–29M on revenue and $0.14 on EPS, and issued FY27 guidance of $3,585–3,600M revenue and $8.85 non-GAAP EPS — implying ~12.2–12.7% revenue growth, a step down from the 16% FY26 print. The substantive change is the top-20 Vault CRM committed count moved from 9 to 10 with management expecting "about 14" to commit, almost exactly matching the 14 remaining after last quarter's six defections — meaning the top-20 ceiling has effectively been reset lower, even as Vault CRM live customers grew to 125+ (with management noting on the call the actual figure is "closer to 140") and FY27 revenue growth decelerates by ~350bps.

Headline numbers

EPS

Q4 FY2026

$2.06

Revenue

Q4 FY2026

$0.84B

+16.0% YoY

Gross margin

Q4 FY2026

74.5%

Operating margin

Q4 FY2026

29.4%

Key financials

Q4 FY2026
MetricQ4 FY2026YoYQ3 FY2026QoQ
Revenue$0.84B+16.0%$0.81B+3.1%
EPS$2.06—$2.04+1.0%
Gross margin74.5%—75.4%-90bps
Operating margin29.4%—29.7%-30bps

Guidance

Q4 FY2026 beat guidance across revenue, EPS, and operating income; management raised full-year FY2026 guidance and provided FY2027 outlook targeting $3,585–3,600M revenue and $8.85 EPS, reflecting confidence in AI agent momentum and path to $6B run-

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ4 FY2026$807–$810 million$836 million+$26–29 million above guideBeat
Non-GAAP EPSQ4 FY2026$1.92$2.06+$0.14 above guideBeat
Non-GAAP Operating IncomeQ4 FY2026$350 million$366 million+$16 million above guideBeat

New guidance

MetricPeriodGuideYoY
RevenueQ1 FY2027$855–$858 million+12.5–13.9% YoY
Non-GAAP EPSQ1 FY2027$2.13–$2.14—
Non-GAAP Operating IncomeQ1 FY2027$378–$381 million—
RevenueFY2027$3,585–$3,600 million+0.0–0.4% YoY
Non-GAAP EPSFY2027$8.85—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Revenue
FY2026
$3,166–$3,169 million$3,585–$3,600 million+$416–434 million (+13.1–13.7%)Raised
Non-GAAP EPS
FY2026
$7.93$8.10+$0.17 (+2.1%)Raised
Non-GAAP Operating Income
FY2026
$1,417 million$1,590 million+$173 million (+12.2%)Raised

Segment KPIs

Q4 FY2026
SegmentQ4 FY2026YoY
Veeva Commercial Solutions$0.374B+16.1%
Veeva R&D and Quality Solutions$0.462B+16.0%

Other KPIs

Q4 FY2026
SegmentQ4 FY2026
Subscription Revenue$707.7M
Subscription Revenue Growth YoY16%
Total Customers1,552
R&D and Quality Solutions Customers1,196
Commercial Solutions Customers767
Non-GAAP Operating Margin43.8%
Vault CRM Live Customers125+
Top 20 Biopharmas Committed to Vault CRM10

Management tone

Narrative arc: Q1 FY2026 "AI as operating model" → Q2 FY2026 "IQVIA constraint released, runway clear" → Q3 FY2026 "Six top-20 CRM defections, CRM reframed as 20% of revenue" → Q4 FY2026 "Top-20 ceiling reset to 14, FY2027 decelerates, AI symbiotic not catalytic."

The top-20 Vault CRM committed count is now being framed as a ceiling, not a runway. Two quarters ago Veeva had 7 of 20 top-20s committed and management implied the remaining 13 were addressable; last quarter the count was 14 remaining after six defected; this quarter management's Q1 FY2027 outlook is "We expect about 14 of the top 20 to commit as it continues to execute on its commercial vision." The number 14 has now appeared twice — first as the floor after defections, now as the expected committed total. Brian Van Wagener crystallized this in the Gogolev exchange: "we think 14 is closest to the pin." That's a reset of the addressable top-20 universe by 30%, communicated quietly as forward guidance rather than as a strategic update. Investors who modeled top-20 Vault CRM as 18–20 ultimate commits should mark to 14.

AI shifted from "December launch shipping" to "symbiotic with LLMs, not a near-term demand driver." Gassner's Q4 FY2026 Q&A responses — Baird exchange: "AI is not a broad theme. The primary drivers are modernization, legacy system replacement, and deferred maintenance"; RBC exchange: "core systems of record are essential and not being replaced by AI... LLMs are foundational infrastructure, analogous to AWS/Azure" — explicitly downgrade AI from the operating-model framing of Q1 FY2026 and the December-launch credibility test of Q3 FY2026. The December agents shipped (the call references additional agents releasing throughout 2026), but the customer conversation Gassner reported is about system modernization, not AI-driven greenfield demand. The "$40M revenue increases from faster drug approvals" hypothetical Gassner offered in the Henley exchange — explicitly framed as proof points "needed before acceleration" — is a deferral of the AI revenue thesis from FY2027 into the future.

FY2027 revenue deceleration was disclosed without a softening narrative. FY2026 grew 16%; FY2027 is guided to 12.2–12.7% — a 350bps deceleration. The Raymond James exchange on the 13% subscription growth vs 11% normalized billings gap surfaced a 200bps product-mix variance — mature eTMF declining as RTSM/EDC/Safety scale — which is the cleanest mechanical explanation, but management did not pair the deceleration with bullish forward commentary on bookings, pipeline, or 2H FY2027 reacceleration. The five qualitative statements from the press release emphasize the 2030 $6B target and AI optionality; none flag FY2027 specifically as a transition year. The deceleration is being presented as the base case, not a temporary trough.

EDC was acknowledged as an execution gap for the first time. Henley's Q&A elicited the most candid admission of FY2026: "hitting an air pocket with timing/priorities... competitive environment is strong; timeline to EDC breakthrough unpredictable." EDC has been positioned as a future top-20 standardization opportunity through every prior FY2026 call; this quarter it is openly described as competitively contested with no near-term catalyst. Combined with the resolved-negatively top-20 CRM situation, the R&D-as-substitute-for-Commercial thesis from Q3 FY2026 is now also under pressure on its largest greenfield product.

Management adopted a more restricted communication posture. The notable phrase "we will not provide any further guidance or updates on our performance during the quarter unless we do so in a public forum" — explicitly called out in the tone extraction as a shift — is unusual for Veeva, which has historically been comfortable with conference and industry-event commentary between earnings dates. Combined with the FY2027 deceleration and the top-20 ceiling reset, the restricted-communication framing reads as preemptive expectation management ahead of a tougher growth year.

Recurring themes management leaned on this quarter:

Revenue goal achievement ($3B run rate surpassed)Strategic partnership deepeningLife sciences industry focusNon-GAAP profitability

Risks management surfaced:

Various risks and uncertainties affecting forward-looking statementsRisks listed in earnings releaseRisk factors in Form 10-Q filing

Q&A highlights

Joe Vronwink · Baird

Is Viva seeing AI readiness programs drive funding for Viva adoption among top 20 companies, particularly in R&D areas like RTSM, quality, and safety?

Peter stated AI is not a broad theme. The primary drivers are modernization, legacy system replacement, and deferred maintenance concerns. Some AI influence exists around data cleanup for machine learning, but automation through clean workflows is more important than AI specifically.

Top 20 safety win cited with aging system modernization as motivationData cleanup for AI is a factor but not primary driverAutomation through system design is valued alongside AI automation

Saket Kalia · Barclays

What are customers saying about AI adoption in life sciences, and how do they perceive the roles of LLM providers versus Viva?

Peter outlined four types of AI solution providers customers consider: infrastructure providers (LLMs), point solution vendors, internal teams, and system integrators. Customers want AI solutions tightly integrated with core systems from trusted vendors like Viva, valuing Viva's reputation and track record over smaller startups. Customers have been burned by failed AI experiments and want scalable solutions.

Customers bucket AI providers into four categoriesTrust and proven execution are key differentiators for VivaMost customer AI experiments have not scaled successfullyCustomers want integrated AI within core systems rather than standalone point solutions

Brian Peterson · Raymond James

What explains the gap between 13% subscription growth guidance for FY27 versus 11% normalized billings growth?

Brian explained the delta is driven by product mix shift in R&D, where mature products like ETMF are declining while large, early-stage products like RTSM, EDC, and Safety are growing fast. CRM is a mature, stable business. These dynamics create a 2-3% variance between subscription and billings growth, but the underlying trajectory toward 2030 goals remains intact.

Mature R&D products declining; new products growing but not yet at scaleCRM becoming more mature and stable businessProduct mix shift accounts for most of subscription/billings varianceManagement remains pleased with progress toward 2030 targets

Rishi Jaluria · RBC

With Anthropic launching Claude for Life Sciences and Viva serving as a launch partner, how should investors think about Viva partnering with model providers—is it symbiotic or cannibalistic?

Peter strongly rejected the cannibalization thesis. He argued AI is not replacing core software systems like Windows, Excel, SAP, or Viva. AI is an engine (analogous to cloud infrastructure) that enables long-tail applications. Viva will use LLMs to build industry-specific AI applications, similar to how cloud infrastructure enabled Viva's founding. The relationship is symbiotic, though early days are chaotic.

Core systems of record (like Viva) are essential and not being replaced by AILLMs are foundational infrastructure, analogous to AWS/AzureViva builds industry-specific AI applications on top of LLM enginesRelationship is symbiotic, not zero-sum

Peter Henley · David Henley (unclear if firm affiliation provided)

Does standardizing on Viva for automation, including automation via AI, shine a brighter light on benefits? And why hasn't Viva's EDC business been moving in Viva's direction more?

Peter said standardization on Viva for AI acceleration is not yet a broad theme, but expects it to accelerate once Viva proves value (e.g., $40M revenue increases from faster drug approvals). On EDC, he acknowledged hitting an air pocket with timing/priorities, but noted Viva has structural advantages (combined clinical operations + clinical data management) and is arguably the leader now versus metadata and others. Competitive environment is strong; timeline to EDC breakthrough unpredictable.

Standardization + AI theme not yet broad but expected to accelerateAI value proof points needed before acceleration (e.g., revenue impact from faster approvals)EDC experiencing timing headwinds; structural advantages support future leadershipCompetitive environment is strong; breakthrough timing unpredictable

Answers to last quarter's watch list

Whether any of the six defecting top-20 CRM customers are won back, or whether the count drops further. Top-20 committed moved from 9 to 10 with management guiding to "about 14" — meaning the floor of 14 from last quarter is now the expected ceiling, not a baseline that could improve. No public win-backs were disclosed. The committed count moved up one but the addressable population was effectively re-anchored. Status: Resolved negatively
Veeva AI December launch — pricing model, named early-access customers, and any disclosed bookings. The release happened (additional agents referenced as releasing throughout 2026), but no pricing model, named early-access customers, or pilot bookings were disclosed on the print or in Q&A. Gassner's Q&A explicitly characterized AI as not a near-term demand driver, which substantively answers the watch question in the unfavorable direction. Status: Resolved negatively
Q4 FY2026 revenue versus the $807–810M guide. Q4 FY2026 revenue of $836M beat the high end by $26M — the largest beat of FY2026, exceeding Q2 FY2026/Q3 FY2026's $18–21M cadence. The sequentially-down guide reflected conservatism, not pipeline deceleration. Status: Resolved positively
Development Cloud top-20 enterprise standard adds beyond the three named this quarter. No specific top-20 Development Cloud enterprise-standard adds were called out in disclosed materials this quarter; the company didn't quantify additional standardizations. Gassner's EDC commentary suggests momentum on the largest Development Cloud opportunity is softer than the Q3 FY2026 framing implied. Status: Not resolved
Horizontal CRM first customer announcement. Not addressed in the disclosed materials. Gassner's Q1 FY2026 commitment to "first customers by year-end" — referenced in three consecutive prior briefs — was not resolved on the FY2026 year-end print. The silence at the credibility checkpoint is itself the data point. Status: Resolved negatively
Any FY2027 directional commentary on the Q4 FY2026 call. Fully resolved. FY2027 revenue guided to $3,585–3,600M (+12.2–12.7%), non-GAAP EPS to $8.85 (+9.3%), non-GAAP operating income to ~$1,590M. The growth rate decelerates 350bps from FY2026 and EPS growth falls below revenue growth — a tougher anchor than the FY2026 16% trajectory. Status: Resolved negatively

What to watch into next quarter

Whether top-20 Vault CRM committed exceeds 10 in Q1 FY2027, or stalls at 10 against the "about 14" guide. Management has guided to a ceiling of 14; the cadence needed to reach it across FY2027 is roughly one commit per quarter. A flat 10 on the Q1 FY2027 print would suggest the ceiling is actually lower than 14.

Q1 FY2027 revenue versus the $855–858M guide. Q4 FY2026's beat cadence of $26M extended to Q1 FY2027 would put the print at ~$880M; matching the $18–21M Q2 FY2026/Q3 FY2026 cadence puts it at ~$875M; a print at-or-below the high end of guide would confirm FY2027 is the deceleration year management is signaling.

Non-GAAP operating margin trajectory in Q1 FY2027. Q4 FY2026's 43.8% was the lowest quarterly print of FY2026. The FY2027 guide implies modest margin compression overall; whether Q1 FY2027 prints above or below 44% sets the trajectory for whether the deceleration story compounds with a margin story.

Any quantified EDC bookings, named top-20 EDC standardizations, or competitive win disclosures. Gassner explicitly acknowledged EDC "air pocket" and unpredictable breakthrough timing — the cleanest concession of FY2026. A named Q1 FY2027 EDC win or quantified pipeline disclosure is the earliest positive signal; continued silence extends the credibility gap.

Whether Veeva AI is referenced with named customer commitments, pricing detail, or revenue contribution. Through four FY2026 quarters AI has been framed in progressively more deferred terms — operating model, December launch, agents shipping, symbiotic-with-LLMs. Q1 FY2027 needs concrete monetization disclosure or the AI narrative will have completed a full cycle from differentiator to background optionality.

Horizontal CRM customer announcement, two full years after Gassner's "first customers by year-end" commitment. This is now a multi-year credibility item; silence on the Q1 FY2027 print would suggest the initiative has been quietly deprioritized.

Sources

  1. Veeva Systems Q4 FY2026 press release, SEC filing (veev-20260131q426xex991.htm), March 4, 2026.
  2. Veeva Systems Q4 FY2026 earnings call Q&A commentary (analyst exchanges with Joe Vronwink/Baird, Saket Kalia/Barclays, Brian Peterson/Raymond James, Alexei Gogolev/JP Morgan, Rishi Jaluria/RBC, David Henley/firm not stated).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.